Clinical characteristics of the 264 tumours are listed including: median age=52; tumour stage (158=t2); nodal status (120=negative); menopausal status (132=pre); ER status (115=+); PR status (159=+) and survival (45=dead).
LOH was detected to varying degrees:
1p36 (D1S612) = 31%; 1p34 (D1S552) = 29%; 1p22 (D1S551) = 25%; 3p25.1
(D3S1286) = 24%; 3p14.3 (D3S1295) = 44%; 6q26-27 (D6S503) = 41%; 8p22
(D8S136) = 49%; 9p21-22(D9S157) = 26%; 11p15 (D11S922) = 25%; 11q23-24
(D11S1998) = 48%; 13q12 (D13S171) = 36%; 13q14 (D13S270) = 34%; 16q24.3
(D16S413) = 57%; 17p13.3 (D17S849) = 53%; 17p13.1 (TP53) = 54%; 17q21.1
(D17S934) = 41%; 18q21.1(D18S474) = 30%; 22q13 (D22S272) = 33%
Co-ordinate losses were identified in 1p34+13q12, 1p34+17p13.3, 1p34+17q21.1, 13q12+17p13.3 and 17q13.3+17q21.1. Four markers and two pairs of markers were found to have significant prognostic value and carried significant relative risk of death (RR):
1p34 - P = 0.0047, RR = 2.3; 13q12 - P = 0.0062, RR = 3.1; 17p13.3 - P = 0.0008, RR = 3.8; 17q21.1-P = 0.0259, RR = 1.8; 1p34 and 17p13.3 - P = 0.0001, RR = 8.6; 13q12 and 17p13.3 - P = 0.0064, RR = 9.6.
Clinical parameters for informative patients at each of the four prognostic loci are given. LOH at 13q12 or 17p13.3 were found to be independent markers by multivariate analysis with hazard ratios of 3.1 and 2.7 respectively.
New marker sets of three markers at each loci were shown to be 100% informative when combined.
Due to wide treatment variation in this cohort, no attempt was made to correlate LOH with survival in individual treatment regimens.